Meaningful positive changes in Ligand Pharmaceuticals Inc (NASDAQ: LGND) fundamentals have recently occurred: the consensus estimate for December, 2025 increased significantly, the stock’s power rating rose above 70, and the consensus estimate for December, 2026 increased significantly.
Ligand Pharmaceuticals Inc (NASDAQ: LGND). Important positive changes in investment behavior have recently occurred: positive upside/downside volume developed.
In light of these very positive signals we are reviewing our current Overall Rating of C. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
Ligand Pharmaceuticals has a current Value Trend Rating of C (Low Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Ligand Pharmaceuticals has a poor Appreciation Score of 16 but a good Power Rating of 72, and the Low Neutral Value Trend Rating results.
Recent Price Action
On 9/5/25, Ligand Pharmaceuticals Inc (NASDAQ: LGND) stock declined slightly by -0.6%, closing at $166.75. Trading volume in this decline was normal. The stock has risen 4.8% during the last week and has been strong relative to the market over the last nine months.
Be the first to comment